Leniolislippertje schreef op 7 juli 2022 12:32:
Voor diegene die nog wel geïnteresseerd zijn in inhoud op gebied van HAE
Pharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13
July 06, 2022 08:10 ET | Source: Pharvaris N.V.
ZUG, Switzerland, July 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced that it will host a virtual webinar, titled Expert Perspectives on HAE: Unmet Needs and Therapeutic Options on Wednesday, July 13, 2022, at 10:00 a.m. ET/16:00 CET.
The virtual event will highlight several topics related to today’s HAE landscape, including a community member and physician perspective, as well as current therapeutic needs, followed by a Q&A session. Presenters for the event are:
- Anthony J. Castaldo, co-founder and President, HAE International (HAEi), and President, U.S. Hereditary Angioedema Association (HAEA)
- Marc A. Riedl, M.D., M.S., Professor of Medicine, Clinical Director of the US Hereditary Angioedema Association (HAEA) Angioedema Center at the University of California San Diego (UCSD), and the Training Program Director for Allergy/Immunology at UCSD
- Berndt Modig, Chief Executive Officer, Pharvaris
- Peng Lu, M.D., Ph.D., Chief Medical Officer, Pharvaris
To register for the live webcast, please visit
ir.pharvaris.com/news-events/events-p... in the News and Events section of the company’s website. Following the live webcast, an archived replay will be available for at least 30 days after the event